Gretchen G. Kimmick, MD, MS:We give adjuvant therapy, which is preventive therapy, for breast cancer. We think it’s fairly easy to decide whether or not to give a pill. As endocrine therapy, the pill options include things like letrozole and tamoxifen, given once per day. The side effects that are seen are mostly menopausal types of side effectshot flashes and some joint stiffness. The bigger decision is whether or not to give chemotherapy. Chemotherapy has higher short-term risks. The regimens cause hair loss, and there are some long-term risks for cardiotoxicity and neuropathy, and those kinds of thing. So, the big decision is whether or not to give chemotherapy in addition to endocrine therapy. That’s where the Oncotype DX score comes in—to help you make that decision.
We also look at the size of the cancer, the lymph node status, and the grade of the cancer when making decision as to whether or not to give chemotherapy. She had a fairly large hormone receptor-positive, HER2 [human epidermal growth factor receptor 2]-negative cancer. It was high risk, based on her Oncotype DX score. I would suggest an anthracycline/taxane chemotherapy regimen based on the fact that the cancer was so large. There is some debate, however, as to whether or not we should be using anthracyclines in that setting.
A trial that studied 6 cycles of Taxotere [docetaxel] with Cytoxan [cyclophosphamide], which is not necessarily a benign regimen, with standard anthracycline/taxane continuing regimens was done. In patients who had lymph nodes that had cancer in them, the anthracycline-containing regimens were better. So, in patients who are at high risk and have lymph nodes that are positive, in whom you’re debating whether to use an anthracycline, I would say to use the anthracycline. However, in patients with negative lymph nodesa tumor of less than 5 cm, or 3 cm, or less—if you’re going to use chemotherapy, 4 or 6 cycles of Taxotere with Cytoxan may be adequate.
For the 5-cm cancer, I think there’s room for debate. Some people would suggest using the 6 cycles of the taxane-containing regimen based on her age, the high grade of the cancer, and the fact that the tumor was so large. I do think it was acceptable to use the taxane and anthracycline-containing regimen in her case.
Transcript edited for clarity.
A 52-Year-Old Woman with MetastaticER+ Breast Cancer
March 2015
April 2017
April 2018
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Survival and Safety Outcomes Factor into Use of Sacituzumab Govitecan in HR+ Breast Cancer
March 29th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor–positive breast cancer in the first article of a 2-part series.
Read More